化疗对骨肉瘤患者血中整合素α2β1的影响

Chemotherapy and integrin α2β1 in the plasma of osteosarcoma patients

目的整合素α2β1为整合素家族成员之一,近来发现整合素在肿瘤的发生发展中起重要作用。文中研究化疗对骨肉瘤患者血中整合素α2β1的影响,探讨其临床意义及在骨肉瘤诊断和治疗中的应用前景。方法收集骨肉瘤患者化疗阶段前后的血浆标本,用ELISA法检测整合素α2β1水平。结果化疗前血浆中整合素α2β1水平为(2.41±0.77)μg/L,化疗后为(1.73±0.56)μg/L,与化疗前相比明显降低,P<0.01。结论化疗能促使骨肉瘤患者血中整合素α2β1下降,提示有效的化疗可能下调骨肉瘤细胞中整合素α2β1的表达,从而改变其相应的生物学活性。整合素有可能成为判断骨肉瘤化疗预后的血液指标。

Objective Integrin α2β1 is a member of the integrin family,which is found to play an important role in the pathogenesis and progression of tumor.This study aimed to investigate the effect of chemotherapy on integrin α2β1 in the plasma of osteosarcoma patients,and to explore the clinical significance of integrin α2β1 and its prospects in the diagnosis and treatment of osteosarcoma.Methods We collected plasma samples from osteosarcoma patients before and after chemotherapy,and detected the levels of integrin α2β1 in the plasma by ELISA.Results The level of integrin α2β1 in the plasma was（1.73±0.56） μg/L after the chemotherapy,significantly reduced in comparison with（2.41±0.77） μg/L before the chemotherapy（P0.01）.Conclusion Chemotherapy can decrease the level of integrin α2β1 in the plasma of osteosarcoma patients,which suggests that effective chemotherapy may down-regulate the expression of integrin α2β1 and alter the biological activity of osteosarcoma cells.Accordingly integrin could be a plasma marker for the prognosis of chemotherapy for osteosarcoma.